10-Fold increase (2006-11) in the rate of healthy subjects with extended-spectrum -lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre
Open Access
- 9 November 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (3) , 562-568
Abstract
In 2006, 0.6% of healthy subjects living in the Paris area had extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in their gut. To assess the evolution of this rate, a study identical to that of 2006 was conducted in 2011. Healthy adults who visited the IPC check-up centre in February–March 2011 and agreed to participate, provided stools and answered a questionnaire on the visit day. Stools were analysed to detect ESBL producers and to isolate the dominant E. coli population. ESBLs were molecularly characterized. For the subjects harbouring ESBL-producing E. coli, the phylogenetic group and sequence type (ST) were determined for both ESBL-producing and dominant E. coli isolates. PFGE profiles were also determined when two types of isolates had the same ST. Among the 345 subjects included, 21 (6%) had ESBL-producing E. coli faecal carriage. None of the previously published risk factors was identified. CTX-M accounted for 86% and SHV-12 for 14%. Dominant and ESBL-producing E. coli were similarly distributed into phylogenetic groups (A, 52%–48%; B1, 5%; B2, 24%–14%; and D, 19%–33%). Dominant and ESBL-producing E. coli displayed a polyclonal structure (18 STs each). However, ST10 and ST131 were identified in dominant and ESBL-producing E. coli isolates from different subjects. Most (20/21) ESBL producers were subdominant and belonged (16/21) to STs different from that of the corresponding dominant E. coli. The 10-fold increase in the rate of healthy subjects with ESBL-producing E. coli faecal carriage over a 5 year period suggests wide dissemination of these isolates in the Parisian community.Keywords
This publication has 39 references indexed in Scilit:
- Community-onset extended-spectrum β-lactamase (ESBL) producing Escherichia coli: Importance of international travelJournal of Infection, 2008
- Absence of CTX-M Enzymes but High Prevalence of Clones, Including Clone ST131, among Fecal Escherichia coli Isolates from Healthy Subjects Living in the Area of Paris, FranceJournal of Clinical Microbiology, 2008
- Faecal carriage of extended-spectrum -lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiologyJournal of Antimicrobial Chemotherapy, 2008
- Rapid Dissemination and Diversity of CTX-M Extended-Spectrum β-Lactamase Genes in Commensal Escherichia coli Isolates from Healthy Children from Low-Resource Settings in Latin AmericaAntimicrobial Agents and Chemotherapy, 2007
- The CTX-M β-lactamase pandemicCurrent Opinion in Microbiology, 2006
- Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the communityJournal of Antimicrobial Chemotherapy, 2005
- Dramatic Increase in Prevalence of Fecal Carriage of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae during Nonoutbreak Situations in SpainJournal of Clinical Microbiology, 2004
- Growing Group of Extended-Spectrum β-Lactamases: the CTX-M EnzymesAntimicrobial Agents and Chemotherapy, 2004
- Extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1989
- Extended Broad-Spectrum -Lactamases Conferring Transferable Resistance to Newer -Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility PatternsClinical Infectious Diseases, 1988